BTIG Maintains Buy on Climb Bio, Raises Price Target to $20

Benzinga Newsdesk www.benzinga.com Positive 75.3%

Neg 0% Neu 0% Pos 75.3%

BTIG analyst Julian Harrison maintains Climb Bio (NASDAQ:CLYM) with a Buy and raises the price target from $19 to $20.

Comments

No comments yet. Be the first!